Navigation Links
MedImmune's Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
Date:8/23/2007

GAITHERSBURG, Md., Aug. 23 /PRNewswire/ -- MedImmune, Inc. today announced that in a Phase 3 study, motavizumab was shown to reduce hospitalizations due to respiratory syncytial virus (RSV) by 83 percent as compared to placebo (8.3 percent in placebo arm vs. 1.4 percent in motavizumab; p<0.001), as the trial's primary endpoint. In addition, the trial showed a 71-percent reduction in the incidence of RSV-specific lower respiratory infections (LRIs) requiring outpatient management (9.5 percent in placebo group and 2.8 percent in the motavizumab group; p<0.001), which was a secondary endpoint.

Motavizumab is an investigational monoclonal antibody (MAb) being evaluated for its potential to prevent serious disease caused by RSV in high-risk pediatric patients. This Phase 3 trial involved 1,410 full-term infants less than six months of age in two Native American populations. In previous medical studies these populations were shown to have high rates of hospitalization due to RSV.

The randomized (2:1), double-blind study was designed to compare monthly intramuscular injections of motavizumab against placebo. After an interim analysis conducted by an independent data safety monitoring committee, the study was unblinded early due to statistical evidence demonstrating that motavizumab reduced RSV hospitalizations and LRIs requiring outpatient medical management within this population. Kate O'Brien, M.D., associate professor at the Center for American Indian Health, Johns Hopkins Bloomberg School of Public Health, served as the study's principal investigator.

"We are pleased with the results of this study which support the positive results seen in our Phase 3 pivotal trial comparing motavizumab and Synagis(R) (palivizumab) that were previously reported at the Pediatric Academic Societies meeting in May 2007," said Genevieve Losonsky, M.D., vice president, clinical development, infectious disease, MedImmune.

Motavizumab was well tolerated in these
'/>"/>

SOURCE MedImmune, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
2. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
3. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
4. Lipitor Reduced the Risk of Coronary Events by Half and Stroke by Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who Experienced a Recent Stroke
5. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
6. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
7. New Analysis of WHI Data Shows Reduced Levels of Coronary Artery Calcification, a Predictor of Cardiovascular Events, in Women aged 50-59 taking Estrogen Therapy
8. Pivotal Phase III Trial Showed Promacta (eltrombopag olamine) Raised Platelet Counts and Reduced Bleeding in Patients With Chronic ITP
9. Preclinical Study Finds Protease Inhibitor-Resistant HIV May Have Reduced Potential to Develop Resistance to Panacos Bevirimat
10. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
11. Data Suggest Cymbalta Reduced Severity of Night Pain in Patients with Diabetic Nerve Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 2014 Capnia, Inc. (NASDAQ: ... diagnostics based on its proprietary Sensalyze™ Technology Platform ... financial results for the third quarter and nine ... the completion of our initial public offering (IPO), ... recently initiated CoSense® commercial launch," said Anish Bhatnagar, ...
(Date:12/19/2014)... 18, 2014 Baptist Health Lexington is the first ... receive full Atrial Fibrillation with Electrophysiology Services (EPS) Accreditation status ... Atrial fibrillation is the most common cardiac arrhythmia and has ... can lead to stroke and possible death. More than 5 ... have atrial fibrillation and the numbers are rapidly increasing as ...
(Date:12/19/2014)... Dec. 18, 2014   Aratana Therapeutics, Inc ... company focused on the licensing, development and commercialization ... positive results from its pivotal field study of ... pain in dogs with osteoarthritis.  In the study, ... scores that were statistically significant compared to placebo ...
Breaking Medicine Technology:Capnia Reports Third Quarter 2014 Financial Results 2Capnia Reports Third Quarter 2014 Financial Results 3Capnia Reports Third Quarter 2014 Financial Results 4Capnia Reports Third Quarter 2014 Financial Results 5Capnia Reports Third Quarter 2014 Financial Results 6Capnia Reports Third Quarter 2014 Financial Results 7Capnia Reports Third Quarter 2014 Financial Results 8Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 2Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5
... Nov. 5, 2011 Savient Pharmaceuticals, Inc. (NASDAQ: ... providing further clarity and context surrounding the risk ... occur with KRYSTEXXA® (pegloticase) in the treatment of ... at the American College of Rheumatology (ACR) Annual ...
... Volcano Corporation (NASDAQ: VOLC ), a ... designed to enhance the treatment of coronary and peripheral ... ( AD enosine V asodilator I ndependent ... by Volcano, will be presented in a Late-Breaking Session ...
Cached Medicine Technology:Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting 2Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting 3Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting 4Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting 5Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting 6Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting 7Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting 8Volcano Corporation Announces Upcoming Presentation of Late-Breaking Clinical Trial Results and FFR Product Launch at TCT 2011 2Volcano Corporation Announces Upcoming Presentation of Late-Breaking Clinical Trial Results and FFR Product Launch at TCT 2011 3Volcano Corporation Announces Upcoming Presentation of Late-Breaking Clinical Trial Results and FFR Product Launch at TCT 2011 4
(Date:12/19/2014)... 19, 2014 Surviving Mesothelioma says thousands of ... indicates that these pipes can leach asbestos into drinking water ... full story on the Surviving Mesothelioma website. , ... natural asbestos deposits, decaying water mains made of asbestos cement ... , To protect consumers from mesothelioma , water providers ...
(Date:12/19/2014)... Thompson HealthDay Reporter ... into the United States -- along with Angelina Jolie,s ... have highlighted cracks in the nation,s public health defense ... report released Thursday. Half of U.S. states are ... disease outbreaks. That was the main conclusion of the ...
(Date:12/19/2014)... LENEXA, Kan. (PRWEB) December 19, 2014 ... dedicated exclusively to healthcare providers, has been retained to ... for Johnson Memorial Hospital in Franklin, Ind. The top ... Smith has recently placed more than 900 healthcare executives ... 100-bed, county-owned, full service hospital providing care to the ...
(Date:12/19/2014)... 2014 Novellus Healthcare Communications, LLC ... & Clinics™, an independent journal that provides practical ... caring for patients inside the pharmacy and retail ... provide optimal access to quality care, Inside Patient ... the team treating and coordinating patient care in ...
(Date:12/19/2014)... 19, 2014 Pain Free Living a ... to announce a new Superior magnetic necklace ... are the strongest neodymium magnets for the fastest pain ... developed the Superior Magnetics brand for the fastest relief ... performs magnetic therapy using Superior Magnetic Jewelry at fairs ...
Breaking Medicine News(10 mins):Health News:Surviving Mesothelioma Warns of Potential Mesothelioma Risk from Cement Water Pipes 2Health News:Most States Not Ready to Handle Infectious Disease Outbreaks: Report 2Health News:Most States Not Ready to Handle Infectious Disease Outbreaks: Report 3Health News:Most States Not Ready to Handle Infectious Disease Outbreaks: Report 4Health News:Johnson Memorial Hospital Retains B. E. Smith to Recruit New Chief Financial Officer 2Health News:Johnson Memorial Hospital Retains B. E. Smith to Recruit New Chief Financial Officer 3Health News:The Transformation of Retail Pharmacies into a Healthcare Delivery Center 2Health News:The Transformation of Retail Pharmacies into a Healthcare Delivery Center 3Health News:New Superior Magnetic Necklace Relieves Migraine Headache 2
... FACS today announced that Paphos Skincare of Ft Lauderdale, FL has finished ... in the World. The Cream is manufactured in Italy and sold worldwide ... ... -- Gary Weinberger, MD, FACS today announced that Paphos Skincare of Ft ...
... psychologists, geneticists and neuroscientists has reported that a safe ... the brain has improved spatial learning and working memory ... human use of the drug, the finding supports the ... cognitive impairment, cushion the cognitive impact of normal aging, ...
... product destroys fat cells while increasing muscle mass without a major decrease ... ... The Total Health and Rejuvenation Center have successfully used their new Hgh ... dieting. Sources at the Total Heath Center have released the preliminary results ...
... in the Feb. 1 issue of the journal SLEEP ... the longitudinal link between sleep problems and depression. Results of ... converse association was not found. These findings are consistent with ... children from the development of depression. , Results of ...
... plays a role, study suggests , , FRIDAY, Jan. 30 ... may be less likely to attempt suicide than others, ... analyzed data from almost 37,000 people who took part ... relationship between spirituality, religious worship and suicidal behavior. , ...
... small arteries at the surface of the brain redirects flow ... tissue starved of nutrients and oxygen following a stroke, a ... news," said David Kleinfeld, a physics professor at the University ... animal models of stroke. , Damage from stroke can continue ...
Cached Medicine News:Health News:The Only 100% Biologically Pure Lycopene Cream in the World 2Health News:Vascular drug found to improve learning and memory in middle-aged rats 2Health News:Study finds genetic link between sleep disorders and depression in young children 2Health News:Study finds genetic link between sleep disorders and depression in young children 3Health News:Mesh-like network of arteries adjusts to restore blood flow to stroke-injured brain 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: